Alberto Lleó Bisa

Alberto Lleó

Dr. Alberto Lleó is the director of the Memory Unit of the Neurology Department at Hospital de la Santa Creu i Sant Pau.

After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona and continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.

In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.

Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.

Recent Publications

  1. LRP10 in α-synucleinopathies. Guerreiro, R, Orme, T, Neto, JL et al. Lancet Neurol 2018
    PMID:30507384

  2. Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Swarup, V, Hinz, FI, Rexach, JE et al. Nat. Med. 2018
    PMID:30510257

  3. A comprehensive screening of copy number variability in dementia with Lewy bodies. Kun-Rodrigues, C, Orme, T, Carmona, S et al. Neurobiol. Aging 2018
    PMID:30448004

  4. Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. Pegueroles, J, Jiménez, A, Vilaplana, E et al. Oncotarget 2018
    PMID:30410669

  5. Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. Giménez, S, Videla, L, Romero, S et al. J Clin Sleep Med 2018
    PMID:30353801

  6. Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Ramos de Matos, M, Ferreira, C, Herukka, SK et al. J. Alzheimers Dis. 2018
    PMID:30320580

  7. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Alcolea, D, Irwin, DJ, Illán-Gala, I et al. J. Neurol. Neurosurg. Psychiatry 2018
    PMID:30297518

  8. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum. Illán-Gala, I, Alcolea, D, Montal, V et al. Neurology 2018
    PMID:30291183

  9. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Bergeron, D, Gorno-Tempini, ML, Rabinovici, GD et al. Ann. Neurol. 2018
    PMID:30255971

  10. A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Zhang, M, Ferrari, R, Tartaglia, MC et al. Brain 2018
    PMID:30252044

  11. Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's Disease. Perea, JR, Lleó, A, Alcolea, D et al. Front Neurosci 2018
    PMID:30245615

  12. Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species. Oliveira, F, Leuzy, A, Castelhano, J et al. Neuroimage Clin 2018
    PMID:30186764

  13. Challenges associated with biomarker-based classification systems for Alzheimer's disease. Illán-Gala, I, Pegueroles, J, Montal, V et al. Alzheimers Dement (Amst) 2018
    PMID:30175226

  14. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Fortea, J, Carmona-Iragui, M, Benejam, B et al. Lancet Neurol 2018
    PMID:30172624

  15. Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. Bos, I, Vos, SJB, Jansen, WJ et al. Front Aging Neurosci 2018
    PMID:29988624

Search PubMed